Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC

Piñero, Federico; Anders, Margarita; Bermúdez, Carla; Demirdjian, Ezequiel; Varón, Adriana; Palazzo, Ana; Rodríguez, Jorge Rodríguez; Beltran, Oscar; Fonseca, Leonardo Gomes da; Ridruejo, Ezequiel; Caballini, Pablo; Tamagnone, Norberto; Reggiardo, Virginia; Cheinquer, Hugo; Araújo, Alexandre de; Arufe, Diego; Marín, Juan Ignacio; Ratusnu, Natalia; Manero, Estela; Perez, Daniela; Villa, Marina; Orozco, Federico; Murga, Dolores; Marciano, Sebastián; Bessone, Fernando; Silva, Marcelo; Mendizábal, Manuel

doi:10.1016/j.aohep.2023.101110

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond bleeding events, the treatment of HCC in patients with decompensated cirrhosis (Child Pugh B or higher), remains challenging and is supported by poor evidence, as clinical trials exclude these patients, mainly for safety reasons but also because liver decompensation represents a competing risk for survival [102][103][104]. At present, Sorafenib is the only TKI approved for Child Pugh B patients.…”

Section: Real-life Studies and Management Of Portal Hypertension In A...mentioning

confidence: 99%

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

De Gaetano,

Pallozzi,

Cerrito

et al. 2024

Cancers

View full text Add to dashboard Cite

The management of CSPH in patients undergoing systemic treatment for HCC has emerged as a critical concern due to the absence of reliable diagnostic criteria and uncertainties surrounding therapeutic approaches. This review aims to underscore the primary pathophysiological aspects linking HCC and PH, while also addressing the current and emerging clinical strategies for the management of portal hypertension. A review of studies from January 2003 to June 2023 was conducted using the PubMed database and employing MeSH terms, such as “hepatocellular carcinoma”, “immune checkpoint inhibitors”, “systemic therapy”, “portal hypertension”, “variceal bleeding” and “tyrosine kinase inhibitors”. Despite promising results of tyrosine kinase inhibitors in animal models for PH and fibrosis, only Sorafenib has demonstrated similar effects in human studies, whereas Lenvatinib appears to promote PH development. The impact of Atezolizumab/Bevacizumab on PH remains uncertain, with an increasing risk of bleeding related to Bevacizumab in patients with prior variceal hemorrhage. Given the absence of specific guidelines, endoscopic surveillance during treatment is advisable, and primary and secondary prophylaxis of variceal bleeding should adhere to the Baveno VII recommendations. Furthermore, in patients with advanced HCC, refinement of diagnostic criteria for CSPH and guidelines for its surveillance are warranted.

show abstract

Section: Real-life Studies and Management Of Portal Hypertension In A...mentioning

confidence: 99%

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

De Gaetano,

Pallozzi,

Cerrito

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.

Piñero,

Mauro,

Casciato

et al. 2024

Annals of Hepatology

View full text Add to dashboard Cite

Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention

Vengateswaran,

Habeeb,

You

et al. 2024

Medicine in Novel Technology and Devices

View full text Add to dashboard Cite

Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC

Cited by 4 publications

References 19 publications

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives

From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.

Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention

Contact Info

Product

Resources

About